Total amount raised
$18 Millions
Latest funding date
7/1/2022
Location
Nucleus has successfully raised significant funding to advance its comprehensive DNA health testing services, which sequence the entire genome for detailed health insights. The company offers a unique approach by analyzing 1,000 times more DNA than competitors, providing actionable guidance for over 900 conditions and traits.
Keep reading to explore the intricacies of Nucleus's fundraising journey and the investors backing this innovative platform.
What Is Nucleus?
Nucleus is a pioneering company in the field of DNA health testing, offering comprehensive genome sequencing to provide detailed health insights. Founded in the United States, Nucleus aims to deliver more accurate and actionable health information compared to other services.
Although the exact founding year and the names of the founders are not specified, Nucleus has quickly established itself as a leader in the industry. The company focuses on sequencing the entire genome, covering over 900 conditions and traits.
With a commitment to innovation and accuracy, Nucleus continues to grow, although the specific number of employees remains undisclosed. Their services are designed to offer better health insights, making them a preferred choice for many seeking detailed genetic information.
How Much Funding Has Nucleus Raised?
- Seed Round
- Amount Raised: $3.5M
- Date: December 2021
- Lead Investors: Founders Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop the initial product and validate the market need for comprehensive genetic testing.
- Seed Round
- Amount Raised: $14M
- Date: July 2022
- Lead Investors: Seven Seven Six
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the team and enhance the technology platform for better genetic insights.
- Series A
- Amount Raised: $14M
- Date: January 2025
- Lead Investors: Seven Seven Six, Founders Fund
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To capitalize on the downfall of consumer genetic testing giants and integrate wearable data with genetic insights.
Total amount raised: $31.5M. Current valuation: Not publicly disclosed.
Key Investors
- Founders Fund
- Details: Founders Fund is a venture capital firm known for backing ambitious and often controversial startups. They have a reputation for investing in transformative companies.
- Investment Focus Areas: Technology, healthcare, high-impact sectors.
- Notable Investments: SpaceX, Palantir, Facebook.
- Seven Seven Six
- Details: Founded by Alexis Ohanian, co-founder of Reddit, Seven Seven Six is a venture capital firm that focuses on early-stage startups.
- Investment Focus Areas: Early-stage startups, technology, healthcare.
- Notable Investments: Not specified.
- Neo
- Details: Neo is an early-stage venture capital firm that invests in technology companies. They are known for their focus on innovative startups.
- Investment Focus Areas: Technology, early-stage startups.
- Notable Investments: Not specified.
- One Eight Capital
- Details: One Eight Capital is a venture capital firm that focuses on high-growth potential companies across various sectors.
- Investment Focus Areas: High-growth potential companies, technology, healthcare.
- Notable Investments: Not specified.
- Giant Step
- Details: Giant Step is a venture capital firm that invests in innovative and scalable technology solutions.
- Investment Focus Areas: Technology, scalable solutions, innovation.
- Notable Investments: Not specified.
What's Next for Nucleus?
Nucleus stands at the forefront of a rapidly evolving healthcare landscape, poised to revolutionize preventative care through comprehensive genetic testing. By integrating wearable data with genetic insights, the company aims to offer a holistic view of personal health, tapping into a market projected to exceed $30 billion within the next five years. This expansion into family health and personalized medication responses positions Nucleus to capture a significant share of the genomics and personalized medicine market.
As the cost of genome sequencing continues to drop, Nucleus is likely to attract further investment to broaden its services and reach. However, the company faces challenges such as competition from established players like 23andMe, ensuring data accuracy, and navigating regulatory requirements. Despite these hurdles, Nucleus's innovative approach and strategic acquisitions, like Cambrean, suggest a promising path forward, potentially making it an attractive acquisition target for larger biotech firms.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay's platform to access comprehensive fundraising data on companies like Nucleus and gather other critical business insights.
Sign up for free on Clay and start making data-driven decisions today.
